Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$50.38 USD
-1.57 (-3.02%)
Updated May 17, 2024 04:00 PM ET
After-Market: $50.41 +0.03 (0.06%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EXAS 50.38 -1.57(-3.02%)
Will EXAS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for EXAS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EXAS
Exact Sciences (EXAS) Q1 Revenues Rise Y/Y, Gross Margin Down
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
EXAS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
Should Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ) Be on Your Investing Radar?
Techne (TECH) Q3 Earnings and Revenues Beat Estimates
Other News for EXAS
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024
Larry Robbins' Glenview Capital takes in Broadcom, exits Intel among Q1 moves
Cologuard’s Market Share Surge Powers Buy Rating
Call and put selling candidates based on recent stock performance - Goldman
Most attractive short-term overwriting stocks for June expiration - Goldman